NIH Considers Grant Caps for Researchers, Raising Questions

A new proposal under consideration at the National Institutes of Health (NIH) is generating intense discussion across the nation's biomedical research community and could have significant implications for Michigan's universities, academic medical centers, and research institutes. 

In early June, NIH issued a Request for Information (RFI) seeking public comment on a proposal that would limit the number of simultaneous Research Project Grants (RPGs) an individual investigator could hold as a principal investigator or multi-principal investigator. NIH is considering possible caps of two, three, or four active grants per investigator and is soliciting feedback from researchers, institutions, and other stakeholders through August 3, 2026. 

At first glance, the proposal may appear to affect only a relatively small number of highly funded investigators. In reality, however, the policy raises fundamental questions about how federal biomedical research dollars should be distributed and how the nation's scientific workforce should be supported. 

NIH argues that concentrating a large number of grants among a relatively small group of investigators may limit opportunities for other researchers and institutions. According to the agency's analysis, a cap of four grants could free approximately $1.3 billion to support roughly 1,900 additional investigators, while a cap of two grants could redirect more than $3.5 billion and support more than 5,200 additional investigators. NIH has framed the proposal as part of a broader effort to improve scientific productivity, strengthen workforce sustainability, broaden geographic participation in research, and create opportunities for a larger pool of investigators. 

For many in Michigan's research community, the proposal touches on a long-running debate. Should federal research funding be concentrated among investigators with proven track records and established research enterprises? Or should more resources be distributed across a broader range of investigators, institutions, and emerging scientific ideas? 

Supporters of a grant cap argue that scientific innovation often comes from new perspectives and that broadening access to NIH funding could help early-career and mid-career investigators establish independent research programs. NIH cites studies suggesting that scientific returns may diminish as funding becomes increasingly concentrated among a small number of laboratories and that smaller research teams can sometimes generate more innovative and transformative work than larger organizations. 

Critics, however, warn that the policy could create unintended consequences. Many of the nation's most productive biomedical researchers oversee multiple large, multidisciplinary projects addressing complex scientific and medical challenges. Limiting the number of grants these investigators can lead could force institutions to restructure research programs, transfer grant leadership, or scale back ambitious initiatives that rely on coordinated teams, specialized infrastructure, and long-established collaborations. 

For Michigan, the stakes are particularly significant. The state's leading research institutions - including the University of Michigan, Michigan State University, Wayne State University, Van Andel Institute, Henry Ford Health, Corewell Health, and other research-intensive organizations - compete for hundreds of millions of dollars in NIH funding annually. While only a subset of investigators would likely be directly affected by a grant cap, the proposal could influence faculty recruitment, laboratory growth, mentoring structures, interdisciplinary collaborations, and the pipeline of discoveries that ultimately feed Michigan's life sciences innovation ecosystem. 

The proposal also arrives amid a broader effort by NIH to reshape aspects of the extramural funding system. In 2025, NIH implemented a limit of six grant applications per principal investigator per year, citing concerns about excessive application volume and the integrity of the review process. The new proposal signals that NIH is increasingly focused not only on how grants are reviewed, but also on how research funding is distributed across the biomedical workforce. 

Importantly, the current proposal is not a final policy. NIH is actively seeking input on whether a cap is warranted, where the threshold should be set, how implementation should occur, and what unintended consequences might result. The agency has suggested a phased implementation approach that would gradually bring investigators into compliance as grants are renewed or reassigned rather than requiring immediate changes to existing awards. 

As organizations representing universities, research institutions, scientific societies, and the life sciences industry evaluate the proposal, the coming months are likely to bring vigorous debate about the future structure of the U.S. biomedical research enterprise. For Michigan's research community, the outcome could influence not only who receives NIH funding, but also how scientific teams are organized, how young investigators advance their careers, and how discoveries move from laboratory benches into new therapies, diagnostics, and technologies. 

Michigan researchers and administrators are encouraged to submit their thoughts on the grant cap proposal by August 3, 2026, to this page - https://rfi.grants.nih.gov/?s=6a1f200c6e0a7544e30b3f12.